The Alliance for Aging Research wants CMS to go through with policy changes that could make many more patients eligible for TAVR. The agency is currently considering the changes, and a final decision is expected in June. 

This Class II recall includes more than 18,000 cannulae used during cardiac surgery.

"Pulmonary embolism is fundamentally a cardiovascular disease, where restoration of hemodynamic stability, beyond simple clot removal, is the key determinant of patient recovery,” one researcher explained. 

The purchase price could end up being closer to $200 million if certain commercial milestones are met.

Ziad Ali, MD, said the new device has completely changed the way he and his colleagues treat patients with calcified coronary artery disease. 

These three-year data represent a major update to one of the more noteworthy TAVR trials in recent memory.

Vivek Reddy, MD, spoke to Cardiovascular Business about some of the biggest trends in electrophysiology today.

Late-breaking data out of EuroPCR focused on 420 patients treated with Boston Scientific's new coronary IVL catheter. Overall, the device was found to be both safe and effective for patients with severe CAD.

Baxdrostat, sold by AstraZeneca under the brand name Baxfendy, is now approved to treat hypertension in combination with other antihypertensive medications.

Samuel Jones, MD, reviews some of the biggest concerns about a new Medicare payment model focused on heart failure care that goes live in 2027.